{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T20:46:32Z","timestamp":1794084392158,"version":"4.8.0"},"reference-count":51,"publisher":"Public Library of Science (PLoS)","issue":"5","license":[{"start":{"date-parts":[[2016,5,11]],"date-time":"2016-05-11T00:00:00Z","timestamp":1462924800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0153740","type":"journal-article","created":{"date-parts":[[2016,5,11]],"date-time":"2016-05-11T13:45:20Z","timestamp":1462974320000},"page":"e0153740","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":105,"title":["Safety and Efficacy of Methotrexate in Psoriasis: A Meta-Analysis of Published Trials"],"prefix":"10.1371","volume":"11","author":[{"given":"Jonathan","family":"West","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Ogston","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Foerster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2016,5,11]]},"reference":[{"issue":"2","key":"ref1","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1111\/bjd.12663","article-title":"Efficacy and safety of systemic treatments for moderate-to-severe psoriasis: meta-analysis of randomized controlled trials","volume":"170","author":"J Schmitt","year":"2014","journal-title":"The British journal of dermatology"},{"issue":"4","key":"ref2","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1136\/ard.2011.152223","article-title":"Infliximab plus methotrexate is superior to methotrexate alone in the treatment of psoriatic arthritis in methotrexate-naive patients: the RESPOND study","volume":"71","author":"A Baranauskaite","year":"2012","journal-title":"Annals of the rheumatic diseases"},{"issue":"5","key":"ref3","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1111\/j.1365-2133.2011.10615.x","article-title":"Efficacy and safety of infliximab vs. methotrexate in patients with moderate-to-severe plaque psoriasis: results of an open-label, active-controlled, randomized trial (RESTORE1)","volume":"165","author":"J Barker","year":"2011","journal-title":"The British journal of dermatology"},{"issue":"22","key":"ref4","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1056\/NEJM200011303432201","article-title":"A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis","volume":"343","author":"JM Bathon","year":"2000","journal-title":"The New England journal of medicine"},{"issue":"1","key":"ref5","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/art.23144","article-title":"Comparison of the clinical efficacy and safety of subcutaneous versus oral administration of methotrexate in patients with active rheumatoid arthritis: results of a six-month, multicenter, randomized, double-blind, controlled, phase IV trial","volume":"58","author":"J Braun","year":"2008","journal-title":"Arthritis and rheumatism"},{"issue":"1","key":"ref6","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1002\/art.21519","article-title":"The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment","volume":"54","author":"FC Breedveld","year":"2006","journal-title":"Arthritis and rheumatism"},{"issue":"2","key":"ref7","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1136\/ard.2006.057133","article-title":"Combination therapy with sulfasalazine and methotrexate is more effective than either drug alone in patients with rheumatoid arthritis with a suboptimal response to sulfasalazine: results from the double-blind placebo-controlled MASCOT study","volume":"66","author":"HA Capell","year":"2007","journal-title":"Annals of the rheumatic diseases"},{"issue":"9","key":"ref8","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1002\/1529-0131(200109)44:9<1984::AID-ART346>3.0.CO;2-B","article-title":"Two-year, blinded, randomized, controlled trial of treatment of active rheumatoid arthritis with leflunomide compared with methotrexate. Utilization of Leflunomide in the Treatment of Rheumatoid Arthritis Trial Investigator Group","volume":"44","author":"S Cohen","year":"2001","journal-title":"Arthritis and rheumatism"},{"issue":"2","key":"ref9","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1002\/art.24266","article-title":"Evaluation of the efficacy and safety of pamapimod, a p38 MAP kinase inhibitor, in a double-blind, methotrexate-controlled study of patients with active rheumatoid arthritis","volume":"60","author":"SB Cohen","year":"2009","journal-title":"Arthritis and rheumatism"},{"issue":"8","key":"ref10","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1002\/art.21142","article-title":"Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis","volume":"52","author":"K De Groot","year":"2005","journal-title":"Arthritis and rheumatism"},{"issue":"4","key":"ref11","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1136\/ard.58.4.220","article-title":"Combination therapy in early rheumatoid arthritis: a randomised, controlled, double blind 52 week clinical trial of sulphasalazine and methotrexate compared with the single components","volume":"58","author":"M Dougados","year":"1999","journal-title":"Annals of the rheumatic diseases"},{"issue":"9636","key":"ref12","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S0140-6736(08)61000-4","article-title":"Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment trial","volume":"372","author":"P Emery","year":"2008","journal-title":"Lancet"},{"issue":"6","key":"ref13","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1093\/rheumatology\/39.6.655","article-title":"A comparison of the efficacy and safety of leflunomide and methotrexate for the treatment of rheumatoid arthritis","volume":"39","author":"P Emery","year":"2000","journal-title":"Rheumatology"},{"issue":"5","key":"ref14","first-page":"292","article-title":"Methotrexate for the treatment of Crohn&apos;s disease. The North American Crohn&apos;s Study Group Investigators","volume":"332","author":"BG Feagan","year":"1995","journal-title":"The New England journal of medicine"},{"issue":"3","key":"ref15","doi-asserted-by":"crossref","first-page":"e384","DOI":"10.1111\/jdv.12004","article-title":"Efficacy and safety of systemic methotrexate vs. acitretin in psoriasis patients with significant palmoplantar involvement: a prospective, randomized study","volume":"27","author":"AB Janagond","year":"2013","journal-title":"Journal of the European Academy of Dermatology and Venereology: JEADV"},{"issue":"1","key":"ref16","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1136\/ard.2008.105197","article-title":"Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study","volume":"69","author":"G Jones","year":"2010","journal-title":"Annals of the rheumatic diseases"},{"issue":"1","key":"ref17","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1136\/annrheumdis-2011-201247","article-title":"Clinical, functional and radiographic consequences of achieving stable low disease activity and remission with adalimumab plus methotrexate or methotrexate alone in early rheumatoid arthritis: 26-week results from the randomised, controlled OPTIMA study","volume":"72","author":"A Kavanaugh","year":"2013","journal-title":"Annals of the rheumatic diseases"},{"issue":"8","key":"ref18","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1093\/rheumatology\/kes001","article-title":"A randomized placebo-controlled trial of methotrexate in psoriatic arthritis","volume":"51","author":"GH Kingsley","year":"2012","journal-title":"Rheumatology"},{"issue":"9410","key":"ref19","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/S0140-6736(04)15640-7","article-title":"Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial","volume":"363","author":"L Klareskog","year":"2004","journal-title":"Lancet"},{"issue":"25","key":"ref20","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1056\/NEJMoa1310476","article-title":"Tofacitinib versus methotrexate in rheumatoid arthritis","volume":"370","author":"EB Lee","year":"2014","journal-title":"The New England journal of medicine"},{"issue":"3","key":"ref21","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1093\/rheumatology\/39.3.316","article-title":"A clinical study of CPH 82 vs methotrexate in early rheumatoid arthritis","volume":"39","author":"T Lerndal","year":"2000","journal-title":"Rheumatology"},{"issue":"7","key":"ref22","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1002\/art.24643","article-title":"Multicenter, randomized, double-blind, controlled trial of treatment of active rheumatoid arthritis with T-614 compared with methotrexate","volume":"61","author":"LJ Lu","year":"2009","journal-title":"Arthritis and rheumatism"},{"issue":"17","key":"ref23","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1056\/NEJMoa1010858","article-title":"A 52-week trial comparing briakinumab with methotrexate in patients with psoriasis","volume":"365","author":"K Reich","year":"2011","journal-title":"The New England journal of medicine"},{"issue":"2","key":"ref24","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1002\/art.33317","article-title":"Safety and efficacy of ocrelizumab in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a forty-eight-week randomized, double-blind, placebo-controlled, parallel-group phase III trial","volume":"64","author":"W Rigby","year":"2012","journal-title":"Arthritis and rheumatism"},{"issue":"3","key":"ref25","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1111\/j.1365-2133.2007.08315.x","article-title":"Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION)","volume":"158","author":"JH Saurat","year":"2008","journal-title":"The British journal of dermatology"},{"issue":"6","key":"ref26","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1136\/ard.2008.101659","article-title":"Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. A randomised controlled trial","volume":"68","author":"J Smolen","year":"2009","journal-title":"Annals of the rheumatic diseases"},{"issue":"9914","key":"ref27","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/S0140-6736(13)61751-1","article-title":"Adjustment of therapy in rheumatoid arthritis on the basis of achievement of stable low disease activity with adalimumab plus methotrexate or methotrexate alone: the randomised controlled OPTIMA trial","volume":"383","author":"JS Smolen","year":"2014","journal-title":"Lancet"},{"issue":"11","key":"ref28","doi-asserted-by":"crossref","first-page":"3432","DOI":"10.1002\/art.20568","article-title":"Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial","volume":"50","author":"EW St Clair","year":"2004","journal-title":"Arthritis and rheumatism"},{"issue":"21","key":"ref29","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1001\/archinte.159.21.2542","article-title":"Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Leflunomide Rheumatoid Arthritis Investigators Group","volume":"159","author":"V Strand","year":"1999","journal-title":"Archives of internal medicine"},{"issue":"4","key":"ref30","doi-asserted-by":"crossref","first-page":"623","DOI":"10.3109\/s10165-012-0742-6","article-title":"A phase 3 randomized, double-blind, multicenter comparative study evaluating the effect of etanercept versus methotrexate on radiographic outcomes, disease activity, and safety in Japanese subjects with active rheumatoid arthritis","volume":"23","author":"T Takeuchi","year":"2013","journal-title":"Modern rheumatology \/ the Japan Rheumatism Association"},{"issue":"6","key":"ref31","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1136\/ard.2011.200317","article-title":"Golimumab in combination with methotrexate in Japanese patients with active rheumatoid arthritis: results of the GO-FORTH study","volume":"71","author":"Y Tanaka","year":"2012","journal-title":"Annals of the rheumatic diseases"},{"issue":"5","key":"ref32","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1002\/art.22525","article-title":"Efficacy of methotrexate treatment in patients with probable rheumatoid arthritis: a double-blind, randomized, placebo-controlled trial","volume":"56","author":"H van Dongen","year":"2007","journal-title":"Arthritis and rheumatism"},{"issue":"12","key":"ref33","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1136\/ard.2008.101121","article-title":"Clinical efficacy and safety of abatacept in methotrexate-naive patients with early rheumatoid arthritis and poor prognostic factors","volume":"68","author":"R Westhovens","year":"2009","journal-title":"Annals of the rheumatic diseases"},{"issue":"5","key":"ref34","doi-asserted-by":"crossref","first-page":"715","DOI":"10.3109\/14397595.2013.864224","article-title":"Efficacy and safety of certolizumab pegol plus methotrexate in Japanese rheumatoid arthritis patients with an inadequate response to methotrexate: the J-RAPID randomized, placebo-controlled trial","volume":"24","author":"K Yamamoto","year":"2014","journal-title":"Modern rheumatology \/ the Japan Rheumatism Association"},{"issue":"7","key":"ref35","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1016\/j.clinthera.2014.05.063","article-title":"Randomized controlled trial comparing 2 different starting doses of methotrexate in rheumatoid arthritis","volume":"36","author":"V Dhir","year":"2014","journal-title":"Clinical therapeutics"},{"issue":"12","key":"ref36","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1111\/j.1468-3083.2010.03667.x","article-title":"Efficacy and safety of mycophenolate mofetil vs. methotrexate for the treatment of chronic plaque psoriasis","volume":"24","author":"M Akhyani","year":"2010","journal-title":"Journal of the European Academy of Dermatology and Venereology: JEADV"},{"issue":"7","key":"ref37","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1111\/j.1365-2230.2012.04440.x","article-title":"Efficacy and safety of systemic methotrexate in two fixed doses of 10 mg or 25 mg orally once weekly in adult patients with severe plaque-type psoriasis: a prospective, randomized, double-blind, dose-ranging study","volume":"37","author":"S Dogra","year":"2012","journal-title":"Clinical and experimental dermatology"},{"issue":"4","key":"ref38","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1111\/j.1365-2133.2010.10195.x","article-title":"Fumarates vs. methotrexate in moderate to severe chronic plaque psoriasis: a multicentre prospective randomized controlled clinical trial","volume":"164","author":"S Fallah Arani","year":"2011","journal-title":"The British journal of dermatology"},{"issue":"1","key":"ref39","first-page":"116","article-title":"Methotrexate vs. ciclosporin in psoriasis: effectiveness, quality of life and safety. A randomized controlled trial","volume":"158","author":"I Flytstrom","year":"2008","journal-title":"The British journal of dermatology"},{"issue":"7","key":"ref40","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1056\/NEJMoa021359","article-title":"Methotrexate versus cyclosporine in moderate-to-severe chronic plaque psoriasis","volume":"349","author":"VM Heydendael","year":"2003","journal-title":"The New England journal of medicine"},{"issue":"1","key":"ref41","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1111\/ijd.12585","article-title":"The efficacy of methotrexate plus pioglitazone vs. methotrexate alone in the management of patients with plaque-type psoriasis: a single-blinded randomized controlled trial","volume":"54","author":"V Lajevardi","year":"2015","journal-title":"International journal of dermatology"},{"issue":"7","key":"ref42","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1111\/j.1365-2230.2009.03693.x","article-title":"Methotrexate versus traditional Chinese medicine in psoriasis: a randomized, placebo-controlled trial to determine efficacy, safety and quality of life","volume":"35","author":"SG Ho","year":"2010","journal-title":"Clinical and experimental dermatology"},{"issue":"10","key":"ref43","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1111\/j.1365-4632.2011.04967.x","article-title":"Weekly vs. daily administration of oral methotrexate (MTX) for generalized plaque psoriasis: a randomized controlled clinical trial","volume":"50","author":"M Radmanesh","year":"2011","journal-title":"International journal of dermatology"},{"issue":"5","key":"ref44","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1080\/09546630701499291","article-title":"Methotrexate versus hydroxycarbamide (hydroxyurea) as a weekly dose to treat moderate-to-severe chronic plaque psoriasis: a comparative study","volume":"18","author":"N Ranjan","year":"2007","journal-title":"The Journal of dermatological treatment"},{"key":"ref45","doi-asserted-by":"crossref","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration&apos;s tool for assessing risk of bias in randomised trials","volume":"343","author":"JP Higgins","year":"2011","journal-title":"Bmj"},{"issue":"2","key":"ref46","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.semarthrit.2015.05.003","article-title":"Risk of liver injury among methotrexate users: A meta-analysis of randomised controlled trials","volume":"45","author":"R Conway","year":"2015","journal-title":"Seminars in arthritis and rheumatism"},{"issue":"6","key":"ref47","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1016\/j.jaad.2015.08.036","article-title":"Can pretreatment serum calcium level predict the efficacy of methotrexate in the treatment of severe plaque psoriasis?","volume":"73","author":"Z Zhai","year":"2015","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"3","key":"ref48","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.jaad.2011.01.022","article-title":"Physician Global Assessment (PGA) and Psoriasis Area and Severity Index (PASI): why do both? A systematic analysis of randomized controlled trials of biologic agents for moderate to severe plaque psoriasis","volume":"66","author":"A Robinson","year":"2012","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"9","key":"ref49","doi-asserted-by":"crossref","first-page":"2489","DOI":"10.1007\/s11136-013-0384-y","article-title":"Psychometric validation of the physician global assessment scale for assessing severity of psoriasis disease activity","volume":"22","author":"JC Cappelleri","year":"2013","journal-title":"Quality of life research: an international journal of quality of life aspects of treatment, care and rehabilitation"},{"issue":"10","key":"ref50","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1016\/j.jclinepi.2009.06.005","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"62","author":"D Moher","year":"2009","journal-title":"Journal of clinical epidemiology"},{"issue":"3","key":"ref51","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1111\/j.1365-2230.1994.tb01167.x","article-title":"Dermatology Life Quality Index (DLQI)\u2014a simple practical measure for routine clinical use","volume":"19","author":"AY Finlay","year":"1994","journal-title":"Clinical and experimental dermatology"}],"updated-by":[{"DOI":"10.1371\/journal.pone.0158928","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2016,7,5]],"date-time":"2016-07-05T00:00:00Z","timestamp":1467676800000}}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0153740","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,9]],"date-time":"2020-05-09T10:08:44Z","timestamp":1589018924000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0153740"}},"subtitle":[],"editor":[{"given":"Arvind","family":"Chopra","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2016,5,11]]},"references-count":51,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2016,5,11]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0153740","relation":{"correction":[{"id-type":"doi","id":"10.1371\/journal.pone.0158928","asserted-by":"object"}]},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,5,11]]}}}